Subodh Verma

MD, FRCSC, FAHA, PhD

Scientist, Keenan Research Centre for Biomedical Science

Biography

Please note: Dr. Verma will not take students in summer.

Dr Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the Canada Research Chair in Cardiovascular Surgery and a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He served as Canada Research Chair in Atherosclerosis for 10 years from 2007-2017. He is an appointee of the
American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar, Dr Verma’s work has been cited nearly 28,000 times resulting in an h-index of 82.

Dr Verma has published numerous times in prestigious journals like the NEJM, Lancet, Circulation, JBC, JACC, Nature, and JCI. He continues to be an active contributor to several CCS guidelines and co-authored the 2018 Diabetes Canada guidelines and 2018 AATS consensus guidelines on bicuspid aortic valve-related aortopathy. Dr Verma has served on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr Verma has leadership roles on 7 ongoing global heart failure trials in diabetes – Dapa-HF, DELIVER, DETERMINE-A, DETERMINE-B, EMPEROR-Preserved, EMPEROR-Reduced and SOLOIST-WHF – as well as the SELECT (semaglutide) and CLEAR SYNERGY (OASIS 9) trials. He oversees the CardioLink platform that is conducting surgically oriented RCTs and translational studies.

Dr Verma oversees a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. This research has yielded 2 United States patents and is currently supported by the Canadian Institutes of Health Research (CIHR) and HSF.

 

Recent Publications

  1. Ferreira, JP, Verma, S, Fitchett, D, Ofstad, AP, Lauer, S, Zwiener, I et al.. Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. Cardiovasc Diabetol. 2020;19 (1):200. doi: 10.1186/s12933-020-01174-6. PubMed PMID:33243221 .
  2. Hess, DA, Trac, JZ, Glazer, SA, Terenzi, DC, Quan, A, Teoh, H et al.. Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. Cell Rep Med. 2020;1 (2):100018. doi: 10.1016/j.xcrm.2020.100018. PubMed PMID:33205058 PubMed Central PMC7659601.
  3. Bhatt, DL, Szarek, M, Steg, PG, Cannon, CP, Leiter, LA, McGuire, DK et al.. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. N Engl J Med. 2020; :. doi: 10.1056/NEJMoa2030183. PubMed PMID:33200892 .
  4. Vallon, V, Verma, S. Effects of SGLT2 Inhibitors on Kidney and Cardiovascular Function. Annu Rev Physiol. 2020; :. doi: 10.1146/annurev-physiol-031620-095920. PubMed PMID:33197224 .
  5. Andrade, JG, Aguilar, M, Atzema, C, Bell, A, Cairns, JA, Cheung, CC et al.. The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation. Can J Cardiol. 2020; :. doi: 10.1016/j.cjca.2020.09.001. PubMed PMID:33191198 .
  6. Goldenberg, RM, Ahooja, V, Clemens, KK, Gilbert, JD, Poddar, M, Verma, S et al.. Practical Considerations and Rationale for Glucagon-like Peptide-1 Receptor Agonist Plus Sodium-Dependent Glucose Cotransporter-2 Inhibitor Combination Therapy in Type 2 Diabetes. Can J Diabetes. 2020; :. doi: 10.1016/j.jcjd.2020.09.005. PubMed PMID:33189580 .
  7. Anker, SD, Butler, J, Filippatos, G, Khan, MS, Marx, N, Lam, CSP et al.. Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial. Circulation. 2020; :. doi: 10.1161/CIRCULATIONAHA.120.051824. PubMed PMID:33175585 .
  8. Dokollari, A, Cameli, M, Bisleri, G, Pervez, MB, Kalra, DK, Demosthenous, M et al.. Mitral Arcades Unexpectedly Encountered During Cardiac Surgery. J Cardiothorac Vasc Anesth. 2020; :. doi: 10.1053/j.jvca.2020.10.018. PubMed PMID:33158711 .
  9. Peterson, BE, Bhatt, DL, Steg, PG, Miller, M, Brinton, EA, Jacobson, TA et al.. Reduction in Revascularization with Icosapent Ethyl: Insights from REDUCE-IT REVASC. Circulation. 2020; :. doi: 10.1161/CIRCULATIONAHA.120.050276. PubMed PMID:33148016 .
  10. Karangelis, D, Mazer, CD, Stakos, D, Tzifa, A, Loggos, S, Verma, S et al.. Cardio-protective effects of sodium-glucose co-transporter 2 inhibitors: focus on heart failure. Curr Pharm Des. 2020; :. doi: 10.2174/1381612826666201103122813. PubMed PMID:33143620 .
Search PubMed

Affiliations & Other Activities

  • Staff Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor, Department of Surgery and Pharmacology & Toxicology, University of Toronto
X